{"id":"alprazolam-xanax","safety":{"commonSideEffects":[{"rate":"50","effect":"Drowsiness"},{"rate":"27","effect":"Lightheadedness"},{"rate":"15","effect":"Dizziness"},{"rate":"40","effect":"Sedation"},{"rate":null,"effect":"Dependence/withdrawal risk"},{"rate":null,"effect":"Cognitive impairment"},{"rate":"10","effect":"Ataxia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alprazolam is a benzodiazepine that binds to GABA-A receptors and potentiates the action of GABA, the primary inhibitory neurotransmitter in the brain. This increases chloride ion influx into neurons, hyperpolarizing the cell membrane and reducing the likelihood of neuronal firing. The result is decreased anxiety, muscle relaxation, and sedation.","oneSentence":"Alprazolam enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, reducing neuronal excitability and producing anxiolytic and sedative effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:26.694Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Generalized anxiety disorder"},{"name":"Panic disorder with or without agoraphobia"},{"name":"Anxiety associated with depression"}]},"trialDetails":[{"nctId":"NCT05077904","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-12-07","conditions":"Stereotypical Prolonged Seizures","enrollment":350},{"nctId":"NCT05076617","phase":"PHASE3","title":"A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures","status":"ENROLLING_BY_INVITATION","sponsor":"UCB Biopharma SRL","startDate":"2022-02-03","conditions":"Stereotypical Prolonged Seizures","enrollment":300},{"nctId":"NCT07020988","phase":"PHASE1","title":"A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2025-06-12","conditions":"Healthy Participants","enrollment":55},{"nctId":"NCT05006079","phase":"PHASE2","title":"Opioid/Benzodiazepine Polydrug Abuse: Aim 3","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2024-03-13","conditions":"Opioid Abuse, Benzodiazepine Abuse, Polysubstance Abuse","enrollment":24},{"nctId":"NCT07275710","phase":"NA","title":"Role of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam.","status":"NOT_YET_RECRUITING","sponsor":"Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi","startDate":"2026-02-01","conditions":"Pain","enrollment":110},{"nctId":"NCT06874452","phase":"PHASE4","title":"An Extension Test of Whether to Use Oral Anti-anxiety Drugs (XANAX) When Patients Choose Second Eye Cataract Surgery After Unblinding, and Analyze Their Anxiety, Satisfaction and Pain Satisfaction","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-03-25","conditions":"Ophthalmology, Cataract Surgery Anesthesia, Oral Anxiolytic","enrollment":250},{"nctId":"NCT06826417","phase":"NA","title":"Anxiety and Surgery Satisfaction for Cataract Patient With Different State Anxiety","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-01-02","conditions":"Oral Anxiolytic, Phacoemulsification, Cataract Surgery","enrollment":400},{"nctId":"NCT07154147","phase":"PHASE4","title":"Oral vs IV Sedation for Cataract Surgery in Older Adults","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-08-12","conditions":"Cataract Surgery, Sedation, Cognition Function","enrollment":20},{"nctId":"NCT06001021","phase":"NA","title":"Cognitive Behavioral Couple Therapy for Perinatal Distress","status":"COMPLETED","sponsor":"Sameera Shafiq","startDate":"2023-08-15","conditions":"Perinatal Depression, Perinatal Anxiety","enrollment":96},{"nctId":"NCT06293638","phase":"","title":"Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2024-03-25","conditions":"Essential Tremor","enrollment":55},{"nctId":"NCT06757140","phase":"PHASE1, PHASE2","title":"Opioid Drug Interaction Study","status":"RECRUITING","sponsor":"Shanna Babalonis, PhD","startDate":"2025-04-01","conditions":"Drug Interactions, Drug Kinetics","enrollment":25},{"nctId":"NCT05602818","phase":"PHASE1","title":"A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-11-15","conditions":"Healthy Volunteers","enrollment":100},{"nctId":"NCT03509285","phase":"PHASE1","title":"A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users","status":"COMPLETED","sponsor":"SK Life Science, Inc.","startDate":"2017-03-08","conditions":"Healthy Volunteer","enrollment":53},{"nctId":"NCT00829426","phase":"PHASE1","title":"Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2005-06","conditions":"Healthy","enrollment":32},{"nctId":"NCT00830024","phase":"PHASE1","title":"Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2005-06","conditions":"Healthy","enrollment":36},{"nctId":"NCT06097676","phase":"PHASE4","title":"An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2021-09-28","conditions":"Abuse Potential","enrollment":86},{"nctId":"NCT00647894","phase":"PHASE1","title":"Fasting Study of Alprazolam Extended-Release Tablets 1 mg to Xanax XR Tablets 1 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT00650299","phase":"PHASE1","title":"Fed Study of Alprazolam Extended-release Tablets 3 mg to Xanax XR® Tablets 3 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-08","conditions":"Healthy","enrollment":21},{"nctId":"NCT00647634","phase":"PHASE1","title":"Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-08","conditions":"Healthy","enrollment":21},{"nctId":"NCT06357104","phase":"PHASE4","title":"Detoxification From the Lipid Tract","status":"COMPLETED","sponsor":"Pachankis, Yang I., M.D.","startDate":"2024-02-26","conditions":"COVID-19 Vaccine Adverse Reaction","enrollment":1},{"nctId":"NCT05626439","phase":"PHASE1","title":"A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2022-12-28","conditions":"Healthy Participants","enrollment":21},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT04802746","phase":"PHASE1","title":"A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-03-09","conditions":"Healthy Study Participants, Participants With Mild Asthma","enrollment":78},{"nctId":"NCT04970342","phase":"PHASE1","title":"Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim","status":"COMPLETED","sponsor":"Timothy L. Brown","startDate":"2021-07-16","conditions":"Driving Behavior, Driving Under the Influence","enrollment":13},{"nctId":"NCT03948243","phase":"PHASE1","title":"Licorice Botanical Dietary Supplements - Metabolism and Safety in Women","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2019-04-01","conditions":"Food-drug Interaction","enrollment":19},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT03635437","phase":"PHASE1, PHASE2","title":"Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes","status":"COMPLETED","sponsor":"Per-Ola Carlsson","startDate":"2018-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":35},{"nctId":"NCT04857307","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-04-28","conditions":"Epilepsy","enrollment":14},{"nctId":"NCT03516305","phase":"PHASE1","title":"Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers","status":"COMPLETED","sponsor":"Engage Therapeutics, Inc.","startDate":"2018-04-06","conditions":"Healthy","enrollment":36},{"nctId":"NCT04592536","phase":"PHASE1","title":"A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects","status":"COMPLETED","sponsor":"Cerevel Therapeutics, LLC","startDate":"2020-10-06","conditions":"Panic Disorder","enrollment":56},{"nctId":"NCT00803400","phase":"PHASE4","title":"Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment","status":"COMPLETED","sponsor":"University of Buenos Aires","startDate":"2008-10-01","conditions":"Panic Disorder","enrollment":150},{"nctId":"NCT02351115","phase":"PHASE2","title":"Staccato Alprazolam and Photoparoxysmal Response","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2015-01","conditions":"Epilepsy","enrollment":5},{"nctId":"NCT04782388","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-03-04","conditions":"Healthy Study Participants","enrollment":30},{"nctId":"NCT03327506","phase":"PHASE4","title":"Preoperative Hypnosis Versus Premedication in Gynecological Surgery","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2018-11-27","conditions":"Gynecologic Disease, Anxiety Disease","enrollment":128},{"nctId":"NCT00368745","phase":"PHASE3","title":"Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-09","conditions":"Generalized Anxiety Disorder","enrollment":108},{"nctId":"NCT03478982","phase":"PHASE2","title":"Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern","status":"COMPLETED","sponsor":"Engage Therapeutics, Inc.","startDate":"2018-03-16","conditions":"Epilepsy","enrollment":156},{"nctId":"NCT00635531","phase":"PHASE4","title":"A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-04","conditions":"Panic Disorder","enrollment":16},{"nctId":"NCT00635076","phase":"PHASE4","title":"A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-07","conditions":"Panic Disorder","enrollment":3},{"nctId":"NCT01322867","phase":"PHASE4","title":"A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-05","conditions":"Healthy","enrollment":30},{"nctId":"NCT00634790","phase":"PHASE4","title":"A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-05","conditions":"Panic Disorder","enrollment":49},{"nctId":"NCT00860119","phase":"PHASE1","title":"Bioequivalence of Alprazolam Sublingual vs Oral Tablets","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2009-08","conditions":"Healthy","enrollment":23},{"nctId":"NCT01330472","phase":"PHASE1","title":"An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-05","conditions":"Healthy Subjects","enrollment":16},{"nctId":"NCT01046162","phase":"PHASE1","title":"A Study Of Two Oral Preparations Of 2 Mg Alprazolam In Healthy Volunteers Under Fasting Conditions","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-07-15","conditions":"Healthy","enrollment":""},{"nctId":"NCT01027689","phase":"PHASE1","title":"Bioequivalence of a New Sublingual and a Reference Alprazolam Immediate Release Tablet Formulation","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-04","conditions":"Healthy","enrollment":""},{"nctId":"NCT00877955","phase":"PHASE1","title":"Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2012-09","conditions":"Healthy","enrollment":""},{"nctId":"NCT00810316","phase":"PHASE1","title":"Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-10","conditions":"Pharmacokinetics","enrollment":24},{"nctId":"NCT01256151","phase":"PHASE1","title":"Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-01","conditions":"Anxiety Disorder","enrollment":28},{"nctId":"NCT01285505","phase":"PHASE1","title":"Bioequivalence of a New and a Commercial Alprazolam Sublingual Formulation","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-04","conditions":"Healthy","enrollment":""},{"nctId":"NCT00245609","phase":"PHASE2","title":"Trial of Pregabalin, Alprazolam, and Placebo in Subjects With Anxiety Prior to Dental Procedure","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-01","conditions":"Dental Anxiety","enrollment":90},{"nctId":"NCT04715269","phase":"PHASE1, PHASE2","title":"Role of Alprazolam in the Management of Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Sohaib Ashraf","startDate":"2020-12-25","conditions":"Acute Coronary Syndrome, Myocardial Infarction, ST Elevation Myocardial Infarction","enrollment":48},{"nctId":"NCT04658732","phase":"PHASE1","title":"A Comparative Study of Oral Gabapentin, Oral Alprazolam and Intravenous Dexmedetomidine on Perioperative Anxiety and Pain During Posterior Segment Eye Surgery Under Peribulbar Block : a Randomized, Double-blind Study.","status":"UNKNOWN","sponsor":"Ehab Tarek Fahmy","startDate":"2020-12-01","conditions":"Sedation for Patients Undergoing Peribulbar Block","enrollment":45},{"nctId":"NCT03702803","phase":"PHASE2","title":"Efficacy and Safety Study of a IMSS Developed Phytopharmaceutical for the Treatment of Anxiety.","status":"UNKNOWN","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2016-03-16","conditions":"Generalized Anxiety Disorder","enrollment":122},{"nctId":"NCT03297944","phase":"PHASE4","title":"Sedative-Anxiolytic Effects on Simulated Driving Performance","status":"COMPLETED","sponsor":"Marion Coe","startDate":"2017-09-15","conditions":"Psychomotor Impairment","enrollment":15},{"nctId":"NCT03286218","phase":"PHASE1","title":"A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-09-15","conditions":"Recreational Drug Use, Prescription Drug Abuse (Not Dependent)","enrollment":96},{"nctId":"NCT03012334","phase":"PHASE1","title":"The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-01-16","conditions":"Migraine","enrollment":90},{"nctId":"NCT00603980","phase":"PHASE1","title":"Staccato Alprazolam Abuse Liability","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2008-01","conditions":"Abuse Liability of Staccato Alprazolam","enrollment":31},{"nctId":"NCT04184141","phase":"PHASE4","title":"Preoperative Use of Alprazolam and Hydroxyzine in Anxiety","status":"UNKNOWN","sponsor":"Istanbul Medeniyet University","startDate":"2019-12-01","conditions":"Agitation on Recovery From Sedation","enrollment":90},{"nctId":"NCT00574639","phase":"EARLY_PHASE1","title":"Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2007-07","conditions":"Type 1 Diabetes","enrollment":14},{"nctId":"NCT00662259","phase":"PHASE4","title":"Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-04","conditions":"Generalized Anxiety Disorder","enrollment":32},{"nctId":"NCT03814733","phase":"PHASE1","title":"Assessment of Effect of Rapastinel on Driving Performance","status":"COMPLETED","sponsor":"Naurex, Inc, an affiliate of Allergan plc","startDate":"2018-11-05","conditions":"Driving Performance","enrollment":107},{"nctId":"NCT02033707","phase":"PHASE1","title":"Effects of Hallucinogens and Other Drugs on Mood and Performance","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-04","conditions":"Healthy","enrollment":20},{"nctId":"NCT01893632","phase":"PHASE2","title":"Gabapentin Treatment of Benzodiazepine Dependence","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2013-07","conditions":"Benzodiazepine Dependence","enrollment":2},{"nctId":"NCT03053869","phase":"PHASE1","title":"Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free)","status":"COMPLETED","sponsor":"McMaster University","startDate":"2017-04-01","conditions":"Post-operative Delirium","enrollment":480},{"nctId":"NCT03576456","phase":"NA","title":"Sedative Premedication in Coronary Angiography","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2019-01-01","conditions":"Coronary Angiography, Sedative Premedication","enrollment":264},{"nctId":"NCT03447353","phase":"PHASE4","title":"Opiates and Benzodiazepines on Driving","status":"COMPLETED","sponsor":"Timothy L. Brown","startDate":"2016-06-14","conditions":"Driving Behavior","enrollment":18},{"nctId":"NCT03398083","phase":"PHASE1","title":"Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2017-12-04","conditions":"Cannabis Use Disorder","enrollment":42},{"nctId":"NCT03220113","phase":"PHASE1, PHASE2","title":"Treatment of Chronic Migraine Headaches.","status":"UNKNOWN","sponsor":"Corona Doctors Medical Clinics, Inc.","startDate":"2017-07-01","conditions":"Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura, Migraine Disorders","enrollment":100},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00426608","phase":"PHASE1","title":"To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-06","conditions":"Depressive Disorder and Anxiety Disorders","enrollment":20},{"nctId":"NCT00555139","phase":"PHASE1","title":"A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-27","conditions":"Social Phobia","enrollment":35},{"nctId":"NCT01745575","phase":"PHASE1","title":"Bioequivalence Trial of Alprazolam 2 mg Tablets","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03-28","conditions":"Anxiety Disorders","enrollment":26},{"nctId":"NCT00477451","phase":"PHASE2","title":"Staccato Alprazolam in Panic Attack","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2007-05","conditions":"Treatment of Induced Panic Attack","enrollment":49},{"nctId":"NCT01853956","phase":"PHASE1","title":"Bioequivalence Trial of Alprazolam 0.25 mg Tablets","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-02","conditions":"Anxiety Disorders","enrollment":28},{"nctId":"NCT01745562","phase":"PHASE1","title":"Bioequivalence Trial of Alprazolam 0.5 mg Tablets","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-07","conditions":"Anxiety Disorders","enrollment":28},{"nctId":"NCT03130842","phase":"PHASE2, PHASE3","title":"Premedication With Alprazolam and Midazolam for Upper Gastrointestinal Endoscopy","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2016-09-17","conditions":"Diagnostic Esophagogastroduodenoscopy","enrollment":136},{"nctId":"NCT01577706","phase":"NA","title":"Spectroscopic Imaging at 4T: A Drug Challenge Study","status":"TERMINATED","sponsor":"Mclean Hospital","startDate":"2013-06","conditions":"AOD Effects and Consequences","enrollment":7},{"nctId":"NCT00913341","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg","status":"COMPLETED","sponsor":"Sandoz","startDate":"1991-11","conditions":"Anxiety","enrollment":30},{"nctId":"NCT00912145","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg","status":"COMPLETED","sponsor":"Sandoz","startDate":"1996-02","conditions":"Anxiety","enrollment":26},{"nctId":"NCT00444522","phase":"PHASE1","title":"Staccato Alprazolam Single Dose PK","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2005-06","conditions":"Healthy","enrollment":50},{"nctId":"NCT02648776","phase":"","title":"Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2016-01","conditions":"Sleep Disorders","enrollment":1400},{"nctId":"NCT00356278","phase":"PHASE2, PHASE3","title":"D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-09","conditions":"Stress Disorder, Post Traumatic","enrollment":156},{"nctId":"NCT02570581","phase":"PHASE1","title":"MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2014-06","conditions":"Healthy","enrollment":16},{"nctId":"NCT01546896","phase":"PHASE4","title":"Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder","status":"WITHDRAWN","sponsor":"Seoul National University Hospital","startDate":"2012-03","conditions":"Anxiety Disorder","enrollment":""},{"nctId":"NCT00703885","phase":"PHASE4","title":"PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-01","conditions":"Anxiety Disorders","enrollment":16},{"nctId":"NCT00592332","phase":"NA","title":"Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2005-06","conditions":"Type 1 Diabetes","enrollment":56},{"nctId":"NCT00266409","phase":"PHASE4","title":"Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-10","conditions":"Generalized Anxiety Disorder, Panic Disorder","enrollment":418},{"nctId":"NCT01949038","phase":"PHASE2, PHASE3","title":"Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2011-09","conditions":"Diagnostic Esophagogastroduodenoscopy","enrollment":220},{"nctId":"NCT01549691","phase":"PHASE4","title":"Reassessment of Premedication in Surgery","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2012-03","conditions":"Anxiety","enrollment":455},{"nctId":"NCT00139854","phase":"PHASE3","title":"A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-08","conditions":"ANXIETY","enrollment":""},{"nctId":"NCT01898897","phase":"NA","title":"Influence of Anesthesia Technique on Postoperative Evolution After Urogenital Surgical Interventions","status":"UNKNOWN","sponsor":"Iuliu Hatieganu University of Medicine and Pharmacy","startDate":"2010-03","conditions":"Anesthesia; Reaction, Adverse Effect of Other General Anesthetics, Adverse Anesthesia Outcome","enrollment":60},{"nctId":"NCT00975481","phase":"PHASE1","title":"A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-10","conditions":"Alzheimer's Disease, Huntington's Disease","enrollment":36},{"nctId":"NCT01747590","phase":"EARLY_PHASE1","title":"Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T","status":"UNKNOWN","sponsor":"Mclean Hospital","startDate":"2011-07","conditions":"Psychotropic Drugs Effects","enrollment":12},{"nctId":"NCT01411813","phase":"","title":"Alprazolam and Eating Behavior in Anorexia Nervosa","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2010-11","conditions":"Anorexia Nervosa","enrollment":19},{"nctId":"NCT01486615","phase":"PHASE4","title":"Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2011-10","conditions":"Anxiety","enrollment":80},{"nctId":"NCT01161472","phase":"PHASE1","title":"A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-07","conditions":"Healthy","enrollment":20},{"nctId":"NCT01546090","phase":"PHASE4","title":"Effect of Alprazolam on the Success of Inferior Alveolar Nerve (IAN) Block","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2011-03","conditions":"Inferior Alveolar Nerve Block Failure","enrollment":60},{"nctId":"NCT01188031","phase":"PHASE1","title":"A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-06","conditions":"Healthy","enrollment":40},{"nctId":"NCT01188057","phase":"PHASE1","title":"A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-07","conditions":"Healthy","enrollment":40},{"nctId":"NCT00865657","phase":"PHASE1","title":"A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT00865761","phase":"PHASE1","title":"A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-09","conditions":"Healthy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"DEPRESSION"},{"count":5,"reaction":"FALL"},{"count":5,"reaction":"GAIT DISTURBANCE"},{"count":5,"reaction":"NAUSEA"},{"count":5,"reaction":"OSTEOPOROSIS"},{"count":4,"reaction":"ASTHENIA"},{"count":4,"reaction":"MALAISE"},{"count":4,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":4,"reaction":"TYPE 2 DIABETES MELLITUS"},{"count":3,"reaction":"ANXIETY"}],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xanax"],"phase":"marketed","status":"active","brandName":"Alprazolam (Xanax)","genericName":"Alprazolam (Xanax)","companyName":"University of California, San Diego","companyId":"university-of-california-san-diego","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alprazolam enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, reducing neuronal excitability and producing anxiolytic and sedative effects. Used for Generalized anxiety disorder, Panic disorder with or without agoraphobia, Anxiety associated with depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}